Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Olema Pharmaceuticals (OLMA) Accumulated Depreciation (2020 - 2023)

Olema Pharmaceuticals (OLMA) has 4 years of Accumulated Depreciation data on record, last reported at $698000.0 in Q3 2023.

  • On a quarterly basis, Accumulated Depreciation rose 44.21% to $698000.0 in Q3 2023 year-over-year; TTM through Sep 2023 was $698000.0, a 44.21% increase, with the full-year FY2022 number at $581000.0, up 159.38% from a year prior.
  • Accumulated Depreciation reached $698000.0 in Q3 2023 per OLMA's latest filing, down from $744000.0 in the prior quarter.
  • Over the last five years, Accumulated Depreciation for OLMA hit a ceiling of $744000.0 in Q2 2023 and a floor of $62000.0 in Q4 2020.
  • A 4-year average of $374833.3 and a median of $350500.0 in 2022 define the central range for Accumulated Depreciation.
  • Peak YoY movement for Accumulated Depreciation: soared 340.0% in 2022, then skyrocketed 44.21% in 2023.
  • Tracing OLMA's Accumulated Depreciation over 4 years: stood at $62000.0 in 2020, then surged by 261.29% to $224000.0 in 2021, then surged by 159.38% to $581000.0 in 2022, then increased by 20.14% to $698000.0 in 2023.
  • Business Quant data shows Accumulated Depreciation for OLMA at $698000.0 in Q3 2023, $744000.0 in Q2 2023, and $681000.0 in Q1 2023.